Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
-
New hope for hard-to-treat lung cancer: experimental drug targets resistant tumors
Disease control Recruiting nowThis study tests a new drug called STX-241 in people with advanced non-small cell lung cancer that has stopped responding to standard targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. The trial will check safety, fi…
Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 17, 2026 04:40 UTC
-
New hope for transplant patients with rare virus-driven cancer
Disease control Recruiting nowThis study tests a treatment called tabelecleucel for people who develop a rare, virus-related cancer after an organ or stem cell transplant and whose cancer did not respond to standard therapy. The treatment uses specially matched immune cells to fight the cancer. About 115 part…
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New hope for hard-to-treat lung cancer: experimental drug targets rare mutations
Disease control Recruiting nowThis study tests an experimental drug called STX-721 in people with advanced non-small cell lung cancer that has specific gene changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if the drug shrinks tumors. About 251 participants will receive the dr…
Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 11, 2026 20:47 UTC